Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) was upgraded by research analysts at Zacks Research to a “hold” rating in a report released on Tuesday,Zacks.com reports. Wall Street Zen upgraded shares of Relmada Therapeutics to a “hold” rating in a research report on Saturday, October 11th. Get Relmada Therapeutics alerts:Check Out Our Latest Research Report on RLMDRelmada Therapeutics Stock Up 0.3%Relmada Therapeutics stock traded up $0.01 during midday trading on Tuesday, reaching $3.96. Relmada Therapeutics Company Profile(Get Free Report)Relmada Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for pain and other central nervous system (CNS) disorders. Recommended StoriesReceive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.